COEP Valuation

Coeptis Therapeutics Holdings Inc

Add to Watchlist

Advanced Chart

11.630

-0.28(-2.351%)1D

Overview
Forecast
Valuation
Earnings

COEP Relative Valuation

COEP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, COEP is overvalued; if below, it's undervalued.

Historical Valuation

Coeptis Therapeutics Holdings Inc (COEP) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -17.91. The fair price of Coeptis Therapeutics Holdings Inc (COEP) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：11.53

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

6.19

P/B

Median3y

8.76

Median5y

17.24

-16.44

FCF Yield

Median3y

-36.28

Median5y

-27.44

Competitors Valuation Multiple

The average P/S ratio for COEP's competitors is 3.04, providing a benchmark for relative valuation. Coeptis Therapeutics Holdings Inc Corp (COEP) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

COEP.O

Coeptis Therapeutics Holdings Inc

Loss

Average P/S: 3.04

40.87M